VAXIMM is a clinical-stage biotech company focused on developing oral T-cell immunotherapies for cancer patients. Based in Switzerland and Germany, their innovative product platform utilizes a modified bacterial vaccine strain to activate patients' cytotoxic T-cells, enabling them to target specific tumor structures. This approach can be adapted to target a wide range of cancer-related antigens.

VAXIMM has a pipeline of development candidates that target different tumor structures, with their lead product candidate, oral VXM01, currently in clinical development for various tumor types, including brain cancer. In collaboration with Merck KGaA, Darmstadt, Germany, VAXIMM has completed a clinical trial evaluating VXM01 alongside the human anti-PD-L1 antibody, avelumab. Additionally, the company has entered into a collaboration agreement with China Medical System Holdings, granting them exclusive rights in China and other Asian countries for VAXIMM's programs.

Headquartered in Basel, Switzerland, VAXIMM is driven by a dedicated management team and subsidiary, VAXIMM GmbH, located in Mannheim, Germany